作者
Jenny J Ko, Wanling Xie, Nils Kroeger, Jae-lyun Lee, Brian I Rini, Jennifer J Knox, Georg A Bjarnason, Sandy Srinivas, Sumanta K Pal, Takeshi Yuasa, Martin Smoragiewicz, Frede Donskov, Ravindran Kanesvaran, Lori Wood, D Scott Ernst, Neeraj Agarwal, Ulka N Vaishampayan, Sun-young Rha, Toni K Choueiri, Daniel YC Heng
发表日期
2015/3/1
期刊
The lancet oncology
卷号
16
期号
3
页码范围
293-300
出版商
Elsevier
简介
Background
Previous prognostic models for second-line systemic therapy in patients with metastatic renal cell carcinoma have not been studied in the setting of targeted therapy. We sought to validate the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model in patients with metastatic renal cell carcinoma receiving next-line targeted therapy after progression on first-line targeted therapy.
Methods
In this population-based study, we analysed patients who received second-line targeted therapy for metastatic renal cell carcinoma at 19 centres in Canada, USA, Greece, Japan, Singapore, South Korea, and Denmark. The primary endpoint was overall survival since the initiation of second-line therapy. We compared the prognostic performance of the IMDC model with the three-factor MSKCC model used for previously treated patients for overall survival since the start of second-line targeted …
学术搜索中的文章
JJ Ko, W Xie, N Kroeger, J Lee, BI Rini, JJ Knox… - The lancet oncology, 2015